China National Medicines Corp Ltd (600511) - Net Assets

Latest as of September 2025: CN¥19.93 Billion CNY ≈ $2.92 Billion USD

Based on the latest financial reports, China National Medicines Corp Ltd (600511) has net assets worth CN¥19.93 Billion CNY (≈ $2.92 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥35.13 Billion ≈ $5.14 Billion USD) and total liabilities (CN¥15.19 Billion ≈ $2.22 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are China National Medicines Corp Ltd's assets to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥19.93 Billion
% of Total Assets	56.74%
Annual Growth Rate	22.37%
5-Year Change	44.91%
10-Year Change	439.94%
Growth Volatility	42.58

China National Medicines Corp Ltd - Net Assets Trend (1999–2024)

This chart illustrates how China National Medicines Corp Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is China National Medicines Corp Ltd's balance sheet for the complete picture of this company's asset base.

Annual Net Assets for China National Medicines Corp Ltd (1999–2024)

The table below shows the annual net assets of China National Medicines Corp Ltd from 1999 to 2024. For live valuation and market cap data, see China National Medicines Corp Ltd market capitalisation.

Year	Net Assets	Change
2024-12-31	CN¥18.98 Billion ≈ $2.78 Billion	+8.22%
2023-12-31	CN¥17.53 Billion ≈ $2.57 Billion	+10.55%
2022-12-31	CN¥15.86 Billion ≈ $2.32 Billion	+10.48%
2021-12-31	CN¥14.36 Billion ≈ $2.10 Billion	+9.63%
2020-12-31	CN¥13.09 Billion ≈ $1.92 Billion	+7.69%
2019-12-31	CN¥12.16 Billion ≈ $1.78 Billion	+14.60%
2018-12-31	CN¥10.61 Billion ≈ $1.55 Billion	+12.19%
2017-12-31	CN¥9.46 Billion ≈ $1.38 Billion	+135.42%
2016-12-31	CN¥4.02 Billion ≈ $587.79 Million	+14.30%
2015-12-31	CN¥3.51 Billion ≈ $514.25 Million	+36.17%
2014-12-31	CN¥2.58 Billion ≈ $377.65 Million	+17.53%
2013-12-31	CN¥2.20 Billion ≈ $321.31 Million	+17.45%
2012-12-31	CN¥1.87 Billion ≈ $273.56 Million	+21.96%
2011-12-31	CN¥1.53 Billion ≈ $224.31 Million	+14.13%
2010-12-31	CN¥1.34 Billion ≈ $196.55 Million	+24.01%
2009-12-31	CN¥1.08 Billion ≈ $158.49 Million	+24.74%
2008-12-31	CN¥868.25 Million ≈ $127.05 Million	+19.60%
2007-12-31	CN¥725.96 Million ≈ $106.23 Million	+22.84%
2006-12-31	CN¥590.99 Million ≈ $86.48 Million	+13.36%
2005-12-31	CN¥521.33 Million ≈ $76.29 Million	+6.75%
2004-12-31	CN¥488.38 Million ≈ $71.47 Million	+4.21%
2003-12-31	CN¥468.65 Million ≈ $68.58 Million	+17.27%
2002-12-31	CN¥399.62 Million ≈ $58.48 Million	+196.51%
2001-12-31	CN¥134.77 Million ≈ $19.72 Million	+8.25%
2000-12-31	CN¥124.50 Million ≈ $18.22 Million	+2.01%
1999-12-31	CN¥122.05 Million ≈ $17.86 Million	--

Equity Component Analysis

This analysis shows how different components contribute to China National Medicines Corp Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 1339036169273.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	CN¥13.39 Billion	78.18%
Common Stock	CN¥754.50 Million	4.41%
Other Comprehensive Income	CN¥27.28 Million	0.16%
Other Components	CN¥2.96 Billion	17.26%
Total Equity	CN¥17.13 Billion	100.00%

China National Medicines Corp Ltd Competitors by Market Cap

The table below lists competitors of China National Medicines Corp Ltd ranked by their market capitalization.

Company	Market Cap
Guangdong Kingshine Electronic Tech SHE:300903	$3.16 Billion
Red Rock Resorts Inc NASDAQ:RRR	$3.17 Billion
ZIM Integrated Shipping Services Ltd NYSE:ZIM	$3.17 Billion
Aerospace CH UAV Co Ltd SHE:002389	$3.17 Billion
Avient Corp NYSE:AVNT	$3.16 Billion
Holitech Technology Co Ltd SHE:002217	$3.16 Billion
Titan Wind Energy Suzhou SHE:002531	$3.16 Billion
Suzhou Recodeal Interconnect System Co Ltd SHG:688800	$3.16 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in China National Medicines Corp Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 15,775,887,678 to 17,128,090,785, a change of 1,352,203,107 (8.6%).
Net income of 2,000,126,950 contributed positively to equity growth.
Dividend payments of 682,430,962 reduced retained earnings.
Other comprehensive income decreased equity by 3,461,287.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥2.00 Billion	+11.68%
Dividends Paid	CN¥682.43 Million	-3.98%
Other Comprehensive Income	CN¥-3.46 Million	-0.02%
Other Changes	CN¥37.97 Million	+0.22%
Total Change	CN¥-	8.57%

Book Value vs Market Value Analysis

This analysis compares China National Medicines Corp Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.26x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 112.44x to 1.26x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
1999-12-31	CN¥0.25	CN¥28.66	x
2000-12-31	CN¥0.26	CN¥28.66	x
2001-12-31	CN¥0.28	CN¥28.66	x
2002-12-31	CN¥0.83	CN¥28.66	x
2003-12-31	CN¥0.90	CN¥28.66	x
2004-12-31	CN¥0.96	CN¥28.66	x
2005-12-31	CN¥1.04	CN¥28.66	x
2006-12-31	CN¥1.17	CN¥28.66	x
2007-12-31	CN¥1.44	CN¥28.66	x
2008-12-31	CN¥1.74	CN¥28.66	x
2009-12-31	CN¥2.18	CN¥28.66	x
2010-12-31	CN¥2.72	CN¥28.66	x
2011-12-31	CN¥3.11	CN¥28.66	x
2012-12-31	CN¥3.75	CN¥28.66	x
2013-12-31	CN¥4.40	CN¥28.66	x
2014-12-31	CN¥5.18	CN¥28.66	x
2015-12-31	CN¥6.33	CN¥28.66	x
2016-12-31	CN¥5.08	CN¥28.66	x
2017-12-31	CN¥11.11	CN¥28.66	x
2018-12-31	CN¥12.04	CN¥28.66	x
2019-12-31	CN¥13.83	CN¥28.66	x
2020-12-31	CN¥15.17	CN¥28.66	x
2021-12-31	CN¥16.94	CN¥28.66	x
2022-12-31	CN¥18.84	CN¥28.66	x
2023-12-31	CN¥20.91	CN¥28.66	x
2024-12-31	CN¥22.70	CN¥28.66	x

Capital Efficiency Dashboard

This dashboard shows how efficiently China National Medicines Corp Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 11.68%
The company shows good efficiency in utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 3.95%
• Asset Turnover: 1.45x
• Equity Multiplier: 2.04x
Recent ROE (11.68%) is below the historical average (15.22%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
1999	8.32%	1.28%	1.39x	4.68x	CN¥-2.05 Million
2000	11.40%	1.27%	2.87x	3.12x	CN¥1.72 Million
2001	14.98%	1.63%	2.80x	3.29x	CN¥6.60 Million
2002	6.57%	2.14%	1.51x	2.03x	CN¥-13.65 Million
2003	7.56%	2.22%	1.35x	2.51x	CN¥-10.57 Million
2004	7.65%	1.95%	1.51x	2.61x	CN¥-10.74 Million
2005	10.12%	2.16%	1.82x	2.57x	CN¥615.16K
2006	14.93%	2.97%	2.06x	2.44x	CN¥27.56 Million
2007	18.96%	3.67%	1.83x	2.83x	CN¥61.95 Million
2008	23.32%	4.42%	2.20x	2.40x	CN¥110.70 Million
2009	21.72%	4.36%	1.87x	2.66x	CN¥122.27 Million
2010	20.02%	4.41%	1.74x	2.60x	CN¥130.67 Million
2011	18.22%	3.85%	1.98x	2.39x	CN¥122.36 Million
2012	18.70%	3.91%	1.88x	2.54x	CN¥156.24 Million
2013	19.53%	4.08%	1.98x	2.41x	CN¥200.78 Million
2014	19.46%	4.18%	2.08x	2.23x	CN¥234.65 Million
2015	16.93%	4.25%	1.84x	2.16x	CN¥209.87 Million
2016	28.12%	2.86%	4.68x	2.10x	CN¥638.00 Million
2017	13.95%	3.15%	1.80x	2.46x	CN¥323.37 Million
2018	15.21%	3.62%	1.80x	2.33x	CN¥480.86 Million
2019	15.22%	3.59%	1.85x	2.30x	CN¥550.19 Million
2020	12.08%	3.42%	1.62x	2.18x	CN¥238.32 Million
2021	13.73%	3.77%	1.69x	2.15x	CN¥476.09 Million
2022	13.82%	4.32%	1.54x	2.08x	CN¥542.58 Million
2023	13.60%	4.32%	1.53x	2.06x	CN¥568.41 Million
2024	11.68%	3.95%	1.45x	2.04x	CN¥287.32 Million

Industry Comparison

This section compares China National Medicines Corp Ltd's net assets metrics with peer companies in the Medical Distribution industry.

Industry Context

Industry: Medical Distribution
Average net assets among peers: $11,236,644,275
Average return on equity (ROE) among peers: 10.83%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
China National Medicines Corp Ltd (600511)	CN¥19.93 Billion	8.32%	0.76x	$3.16 Billion
China National Accord Medicines Corp Ltd (000028)	$8.91 Billion	13.31%	1.39x	$1.74 Billion
Shenzhen Glory Medical Co Ltd (002551)	$2.82 Billion	2.12%	0.68x	$442.93 Million
Shandong Realcan Pharmaceutical Co Ltd (002589)	$5.64 Billion	0.36%	1.96x	$700.19 Million
China National Accord Medicines Corp Ltd (200028)	$357.13 Million	11.35%	0.25x	$126.15 Million
Qingdao Baheal Medical INC. (301015)	$2.60 Billion	26.55%	1.73x	$1.90 Billion
China Meheco Co Ltd (600056)	$1.54 Billion	15.23%	0.77x	$2.27 Billion
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332)	$33.64 Billion	11.79%	1.22x	$4.66 Billion
Liaoning Cheng Da Co Ltd (600739)	$20.00 Billion	4.74%	0.66x	$2.66 Billion
Jointown Pharmaceutical Group Co Ltd (600998)	$25.62 Billion	12.00%	2.16x	$3.81 Billion

About China National Medicines Corp Ltd

SHG:600511 China Medical Distribution

Market Cap

$3.16 Billion

CN¥21.62 Billion CNY

Market Cap Rank

#4776 Global

#884 in China

Share Price

CN¥28.66

Change (1 day)

-0.24%

52-Week Range

CN¥28.06 - CN¥31.21

All Time High

CN¥57.66